Trial Profile
A Randomized, Multicenter, Two-Arm, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3 Study of Intravesical Qapzola (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumors in Patients With Low- to Intermediate-Risk Non-Muscle Invasive Bladder Cancer (CONQUER)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Apaziquone (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms CONQUER
- Sponsors Spectrum Pharmaceuticals
- 30 Aug 2021 Status changed from active, no longer recruiting to discontinued.
- 05 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.